1. A9.03 Exploring the potential of haeme-oxygenase 1 (HO-1) as a therapeutic target for pah associated with CTD. (24th February 2016) Authors: Elies, J; Peers C, C; Del Galdo, F Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. Issue 4 (28th February 2022) Authors: Ajjan, R A; Hensor, E M A; Del Galdo, F; Shams, K; Abbas, A; Fairclough, R J; Webber, L; Pegg, L; Freeman, A; Taylor, A E; Arlt, W; Morgan, A W; Tahrani, A A; Stewart, P M; Russell, D A; Tiganescu, A Journal: European journal of endocrinology Issue: Volume 186:Issue 4(2022) Page Start: 441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. There is a need for new systemic sclerosis subset criteria. A content analytic approach. (2nd January 2018) Authors: Johnson, SR; Soowamber, ML; Fransen, J; Khanna, D; Van Den Hoogen, F; Baron, M; Matucci-Cerinic, M; Denton, CP; Medsger, TA; Carreira, PE; Riemekasten, G; Distler, J; Gabrielli, A; Steen, V; Chung, L; Silver, R; Varga, J; Müller-Ladner, U; Vonk, MC; Walker, UA Journal: Scandinavian journal of rheumatology Issue: Volume 47:Number 1(2018) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗